Ixekizumab interacts in the following cases:
Ixekizumab should not be used with live vaccines. No data are available on the response to live vaccines; there are insufficient data on response to inactive vaccines.
Ixekizumab should be used with caution in patients with clinically important chronic infection or a history of recurrent infection.
Ixekizumab is not recommended in patients with inflammatory bowel disease.
There is a limited amount of data from the use of ixekizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or post-natal development. As a precautionary measure, it is preferable to avoid the use of ixekizumab during pregnancy.
It is not known whether ixekizumab is excreted in human milk or absorbed systemically after ingestion. However, ixekizumab is excreted at low levels in the milk of cynomolgus monkeys. A decision should be made whether to discontinue breast-feeding or to discontinue ixekizumab taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Women of childbearing potential should use an effective method of contraception during treatment and for at least 10 weeks after treatment.
The effect of ixekizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.
Ixekizumab has no or negligible influence on the ability to drive and use machines.
The most frequently reported adverse reactions were injection site reactions (15.5%) and upper respiratory tract infections (16.4%) (most frequently nasopharyngitis).
Adverse reactions from clinical studies and post-marketing reports are listed by MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1 000 to <1/100); rare (≥1/10 000 to <1/1 000); very rare (<1/10 000).
A total of 8 956 patients have been treated with ixekizumab in blinded and open-label clinical studies in plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and other autoimmune conditions. Of these, 6 385 patients were exposed to ixekizumab for at least one year, cumulatively representing 19 833 adult patient years of exposure and 196 children cumulatively representing 207 patient years of exposure.
List of adverse reactions in clinical studies and post-marketing reports:
| System organ class | Frequency | Adverse reaction |
|---|---|---|
| Infections and infestations | Very common | Upper respiratory tract infection |
| Common | Tinea infection, Herpes simplex (mucocutaneous) | |
| Uncommon | Influenza, Rhinitis, Oral candidiasis, Conjunctivitis, Cellulitis | |
| Rare | Oesophageal candidiasis | |
| Blood and lymphatic system disorders | Uncommon | Neutropenia, Thrombocytopenia |
| Immune system disorders | Uncommon | Angioedema |
| Rare | Anaphylaxis | |
| Respiratory, thoracic and mediastinal disorders | Common | Oropharyngeal pain |
| Gastrointestinal disorders | Common | Nausea |
| Uncommon | Inflammatory bowel disease | |
| Skin and subcutaneous disorders | Uncommon | Urticaria, Rash, Eczema |
| General disorders and administration site conditions | Very common | Injection site reactionsa |
a See section description of selected adverse reactions
The most frequent injection site reactions observed were erythema and pain. These reactions were predominantly mild to moderate in severity and did not lead to discontinuation of ixekizumab. In the adult plaque psoriasis studies, injection site reactions were more common in subjects with a body weight <60 kg compared with the group with a body weight ≥60 kg (25% vs. 14% for the combined Q2W and Q4W groups). In the psoriatic arthritis studies, injection site reactions were more common in subjects with a body weight <100 kg compared with the group with a body weight ≥100 kg (24% vs. 13% for the combined Q2W and Q4W groups). In the axial spondyloarthritis studies, injection site reactions were similar in subjects with a body weight <100 kg compared with the group with a body weight ≥100 kg (14% vs. 9% for the combined Q2W and Q4W groups). The increased frequency of injection site reactions in the combined Q2W and Q4W groups did not result in an increase in discontinuations in either the plaque psoriasis, the psoriatic arthritis or the axial spondyloarthritis studies.
The results described above are obtained with the original formulation of ixekizumab. In a single-blinded, randomised cross-over study in 45 healthy subjects comparing the original formulation with the revised, citrate-free formulation, statistically significantly lower Visual Analogue Scale (VAS) pain scores were obtained with the citrate-free vs. the original formulation during injection (difference in LS Mean VAS score -21.69) and 10 min after injection (difference in LS Mean VAS score -4.47).
In the placebo-controlled period of the phase III clinical studies in plaque psoriasis in adults, infections were reported in 27.2% of patients treated with ixekizumab for up to 12 weeks compared with 22.9% of patients treated with placebo.
The majority of infections were non-serious and mild to moderate in severity, most of which did not necessitate treatment discontinuation. Serious infections occurred in 13 (0.6%) of patients treated with ixekizumab and in 3 (0.4%) of patients treated with placebo. Over the entire treatment period infections were reported in 52.8% of patients treated with ixekizumab (46.9 per 100 patient years). Serious infections were reported in 1.6% of patients treated with ixekizumab (1.5 per 100 patient years).
Infection rates observed in psoriatic arthritis and axial spondyloarthritis clinical studies were similar to those observed in the plaque psoriasis studies with the exception of the frequencies of the adverse reactions of influenza and conjunctivitis which were common in patients with psoriatic arthritis.
In plaque psoriasis studies, 9% of patients receiving ixekizumab developed neutropenia. In most cases, the blood neutrophil count was ≥1 000 cells/mm³. Such levels of neutropenia may persist, fluctuate or be transient. 0.1% of patients receiving ixekizumab developed a neutrophil count <1 000 cells/mm³. In general, neutropenia did not require discontinuation of ixekizumab. 3% of patients exposed to ixekizumab had a shift from a normal baseline platelet value to <150 000 platelet cells/mm³ to ≥75 000 cells/mm³. Thrombocytopenia may persist, fluctuate or be transient.
The frequency of neutropenia and thrombocytopenia in psoriatic arthritis and axial spondyloarthritis clinical studies is similar to that observed in the plaque psoriasis studies.
Approximately 9–17% of adult plaque psoriasis patients treated with ixekizumab at the recommended dosing regimen developed anti-drug antibodies, the majority of which were low titres and not associated with reduced clinical response up to 60 weeks of treatment. However, approximately 1% of patients treated with ixekizumab had confirmed neutralising antibodies associated with low drug concentrations and reduced clinical response.
In psoriatic arthritis patients treated with ixekizumab at the recommended dosing regimen up to 52 weeks, approximately 11% developed anti-drug antibodies, the majority of which were low titre, and approximately 8% had confirmed neutralising antibodies. No apparent association between the presence of neutralising antibodies and impact on drug concentration or efficacy was observed.
In paediatric psoriasis patients treated with ixekizumab at the recommended dosing regimen up to 12 weeks, 21 patients (18%) developed anti-drug antibodies, approximately half were low titer and 5 patients (4%) had confirmed neutralizing antibodies associated with low drug concentrations. There was no association with clinical response or adverse events.
In radiographic axial spondyloarthritis patients treated with ixekizumab at the recommended dosing regimen up to 16 weeks, 5.2% developed anti-drug antibodies, the majority of which were low titer, and 1.5% (3 patients) had neutralising antibodies (NAb). In these 3 patients, NAb-positive samples had low ixekizumab concentrations and none of these patients achieved an ASAS40 response. In non-radiographic axial spondyloarthritis patients treated with ixekizumab at the recommended dosing regimen for up to 52 weeks, 8.9% developed anti-drug antibodies, all of which were low titer; no patient had neutralising antibodies; and no apparent association between the presence of anti-drug antibodies and drug concentration, efficacy, or safety was observed.
Across all indications, an association between immunogenicity and treatment emergent adverse events has not been clearly established.
The safety profile observed in children with plaque psoriasis treated with ixekizumab every 4 weeks is consistent with the safety profile in adult patients with plaque psoriasis with the exception of the frequencies of conjunctivitis, influenza, and urticaria which were common. Inflammatory bowel disease was also more frequent in paediatric patients, although it was still uncommon. In the paediatric clinical study, Crohn's disease occurred in 0.9% of patients in the ixekizumab group and 0% of patients in the placebo group during the 12-week, placebo-controlled period. Crohn's disease occurred in a total of 4 ixekizumab treated subjects (2.0%) during the combined placebo-controlled and maintenance periods of the paediatric clinical study.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.